Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | SRF114 |
| Trade Name | |
| Synonyms | SRF-114|SRF 114|CHS-114|CHS114|CHS 114 |
| Drug Descriptions |
SRF114 is a monoclonal antibody that targets CCR8, which potentially induces antibody-dependent cellular cytotoxicity against CCR8-expressing T-regulatory cells and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2020;8; Journal for ImmunoTherapy of Cancer 2022;10). |
| DrugClasses | CCR8 Antibody 13 |
| CAS Registry Number | NA |
| NCIT ID | C198695 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cisplatin + Fluorouracil + SRF114 + Toripalimab-tpzi | Cisplatin Fluorouracil SRF114 Toripalimab-tpzi | 0 | 1 |
| SRF114 | SRF114 | 0 | 1 |
| SRF114 + Toripalimab-tpzi | SRF114 Toripalimab-tpzi | 0 | 2 |